Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Hyperthermic intraperitoneal chemotherapy (HIPEC) is an advanced procedure where heated chemotherapy is administered directly to cancer sites during surgery. This innovative procedure is used to treat cancer that has spread to the abdominal cavity, including cancers of the stomach, colon, appendix, large and small intestines, and ovaries. HIPEC has been shown to extend survival rates of patients with these types of abdominal cancers.
In a study conducted by The Netherlands Cancer Institute, where HIPEC has been performed since 1995, patients with end-stage cancer lived an average of 21 months longer after receiving this treatment. In addition, the Society of Surgical Oncology recently published a consensus statement on the use of cytoreductive surgery with intraperitoneal hyperthermic chemotherapy in treating carcinomatosis arising from colorectal cancer. This paper, written in part by Dr. Quiñones, provides guidance and sets the standards for the administration of this highly advanced and aggressive approach.
Michael Quiñones, M.D., a fellowship-trained surgical oncologist, was the first surgeon in Georgia to perform this procedure and has been doing so for 15 years.
DeKalb Medical and Dr. Quiñones have established a Peritoneal Malignancy Service. This multidisciplinary team includes Dr. Quiñones, a medical oncologist, general surgeon, gynecological oncologist and gastroenterologist. It functions as a multidisciplinary care conference as it considers each referral and reports its recommendations to you and to your patient. If the decision is made to pursue HIPEC, the team will treat patients at DeKalb Medical.
For more information, call the Peritoneal Malignancy Service’s Easy Access line